FCSC Fibrocell Science Inc.

+0.02  (+1%)
Previous Close 1.8
Open 1.82
Price To Book 2.94
Market Cap 17,760,164
Shares 9,758,332
Volume 92,326
Short Ratio
Av. Daily Volume 45,568

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Phase 2 endpoints not met - June 2016
Chronic Dysphonia
Phase 3 data due 4Q 2020.
Recessive dystrophic epidermolysis bullosa
Phase 1 part of trial to complete enrolment 3Q 2019. Data due mid-2020.

Latest News

  1. The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings
  2. Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
  3. How Fibrocell Science, Inc. (NASDAQ:FCSC) Can Impact Your Portfolio Volatility
  4. Savara Plunges on Failure of Late-Stage Study on Molgradex
  5. Fibrocell Up on FDA Designation for Gene Therapy Candidate
  6. Fibrocell to Present at BIO International Convention 2019
  7. Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?
  8. Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
  9. The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
  10. Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1
  11. Small Business Optimism Hits 4-Month High in April: 5 Picks
  12. Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
  13. Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?
  14. Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
  15. Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
  16. Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
  17. Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
  18. Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
  19. Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
  20. Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates